The Effect of Insulin Use On Body Mass Index in Type 2 Diabetes Mellitus Patients at RSAL Mintohardjo
DOI:
https://doi.org/10.35451/jfm.v9i1.3680Keywords:
Type 2 Diabetes Mellitus, Insulin, Body Mass Index, Corticosteroids, MetforminAbstract
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia due to insulin resistance and impaired insulin secretion. Insulin therapy is widely used in T2DM management; however, it may affect body weight and Body Mass Index (BMI). This study aimed to determine the effect of insulin use on BMI in Type 2 Diabetes Mellitus patients at RSAL Mintohardjo in 2025. This study used a retrospective cohort design with a quantitative approach. A total of 150 patients were selected using a total sampling technique from outpatient medical records that met the inclusion and exclusion criteria. The independent variable was insulin use, while BMI was the dependent variable. Corticosteroid and metformin use were included as confounding variables. Data analysis was conducted using univariate and bivariate analysis with the Wilcoxon Signed-Rank Test. The results showed that most respondents were male (54.7%) and aged ≥60 years (62.7%). Insulin therapy was used by 32.7% of patients, while metformin was used by 73.3% and corticosteroids by 17.3% of patients. The mean BMI category increased from 3.04 ± 1.016 before insulin therapy to 3.39 ± 1.116 after insulin therapy. The Wilcoxon Signed-Rank Test showed a significant difference between BMI before and after insulin therapy (p <0.001). In conclusion, insulin use significantly affected BMI changes in Type 2 Diabetes Mellitus patients at RSAL Mintohardjo. Regular monitoring of nutritional status and body weight is important in patients receiving insulin therapy.
Downloads
References
[1] ADA, “6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024,” Diabetes Care, vol. 47, pp. S111–S125, Jan. 2024, doi: 10.2337/dc24-S006.
[2] P. Saeedi et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition,” Diabetes Res. Clin. Pract., vol. 157, Nov. 2019, doi: 10.1016/j.diabres.2019.107843.
[3] International Diabetes Federation, “International Diabetes Federation: Diabetes Atlas 10th edition,” 2021. [Online]. Available: www.diabetesatlas.org
[4] Y. Zheng, S. H. Ley, and F. B. Hu, “Global aetiology and epidemiology of type 2 diabetes mellitus and its complications,” 2018, Nature Publishing Group. doi: 10.1038/nrendo.2017.151.
[5] R. Ruze et al., “Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments,” 2023, Frontiers Media S.A. doi: 10.3389/fendo.2023.1161521.
[6] Indri Mulyasari, Puji Afiatna, Sugeng Maryanto, and Aisyah Nur Aryani, “Indeks Massa Tubuh sebagai Prediktor Hipertensi: Perbandingan Standar World Health Organization dan Asia-Pasifik,” Dec. 2023.
[7] PERKENI, “Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2024 Perkumpulan Endokrinologi Indonesia,” 2024.
[8] A. Hafizi, N. F. Hasbie, A. Febriyani, and M. Kurniati, “Hubungan Antara Usia, Jenis Kelamin Dan Indeks Massa Tubuh Dengan Kejadian Diabetes Mellitus Tipe 2 Di Rumah Sakit Pertamina Bintang Amin Husada,” 2024.
[9] M. Emad-Eldin, G. F. Balata, E. A. Elshorbagy, M. S. Hamed, and M. S. Attia, “Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges,” World J. Diabetes, vol. 15, no. 5, pp. 828–852, May 2024, doi: 10.4239/wjd.v15.i5.828.
[10] M. A. Edens, P. R. van Dijk, E. Hak, and H. J. G. Bilo, “Determinants of excessive weight gain after the initiation of insulin therapy in type 2 diabetes mellitus: Retrospective inception cohort study (ZODIAC 60),” Diabetes Res. Clin. Pract., vol. 200, Jun. 2023, doi: 10.1016/j.diabres.2023.110719.
[11] N. Prinz et al., “Not All Type-2-Diabetes Patients Increase Body Mass Index after Initiating Insulin: Results of Latent Class Analysis from the DPV Registry,” Diabetes Technol. Ther., vol. 23, no. 12, pp. 799–806, Dec. 2021, doi: 10.1089/dia.2021.0144.
[12] X. Huang, Y. Wu, Y. Ni, H. Xu, and Y. He, “Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021,” Front. Public Health, vol. 13, 2025, doi: 10.3389/fpubh.2025.1515797.
[13] M. Solymár et al., “Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly – A meta-analysis,” PLoS One, vol. 13, no. 11, Nov. 2018, doi: 10.1371/journal.pone.0207947.
[14] E. Akalestou, L. Genser, and G. A. Rutter, “Glucocorticoid Metabolism in Obesity and Following Weight Loss,” Feb. 20, 2020, Frontiers Media S.A. doi: 10.3389/fendo.2020.00059.
[15] W. Oktaviana and S. Wahyuningsih, “Narrative Review: A Comparative Analysis Of The Effectiveness Of Insulin And OAD Treatment in BPJS Outpatients Patients With Type 2 Diabetes Mellitus Various Hospitals In Indonesia,” JURNAL FARMASIMED (JFM), vol. 8, no. 2, pp. 921–931, Apr. 2026, doi: 10.35451/x7rzrg82.
[16] S. Saragi and R. Fitriana, “Drug Interactions in Type 2 Diabetes and Hypertension Patients at RSUD dr. Zainoel Abidin, Banda Aceh,” JURNAL FARMASIMED (JFM), vol. 8, no. 2, pp. 498–508, Apr. 2026, doi: 10.35451/34ygtz72.
[17] C. S. Damanik, K. Khairunnisa, and W. Wiryanto, “Implementation of Pharmaceutical Care to Improve Therapeutic Outcomes and Quality of Life in Type 2 Diabetes Mellitus Patients at Batubara Public Health Center,” JURNAL FARMASIMED (JFM), vol. 8, no. 2, pp. 520–530, Apr. 2026, doi: 10.35451/bym4fr96.
[18] J. H. Cho and S. Suh, “Glucocorticoid-Induced Hyperglycemia: A Neglected Problem,” Apr. 01, 2024, Korean Endocrine Society. doi: 10.3803/EnM.2024.1951.
[19] WHO Asia Pasific, “The Asia-Pacific perspective: Redefining obesity and its treatment,” 2000.
[20] Z. Memon, N. Anjum, and S. S. Sheikh, “Clinicohistological correlation and cost-effectiveness of routinely performed histological examination of pregnancy tissues obtained at uterine evacuation procedure: Five-year experience at a secondary care hospital of Karachi, Pakistan,” Journal of South Asian Federation of Obstetrics and Gynaecology, vol. 9, no. 1, pp. 1–4, Mar. 2017, doi: 10.5005/jp-journals-10006-1446.
[21] American Diabetes Association, “2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024,” Diabetes Care, vol. 47, pp. S20–S42, Jan. 2024, doi: 10.2337/dc24-S002.
[22] B. Sirisha Kusuma, T. Xanthippi, H. A. Emile J., T. Ajay, and M. M. Loredana, “The Relationship between HbA1c and Glucose Management Indicator and Time in Range in Youth with Type 1 Diabetes: A Single Centre Study,” Int. J. Diabetes Clin. Res., vol. 11, no. 1, Jun. 2024, doi: 10.23937/2377-3634/1410183.
[23] F. Apriliany, E. Cholisah, and K. Erlianti, “Efek Pemberian Metformin dan Metformin+Glimepiride terhadap Kadar HbA1c pada Pasien Diabetes Mellitus Tipe 2,” JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), vol. 12, no. 2, p. 97, Jun. 2022, doi: 10.22146/jmpf.72192.
[24] S. I. Abdallah, N. E. Abubaker, M. A. Ibrahim, A. Abd Alla, and R. A. Humaida, “Plasma glucose, HbA1c, insulin and lipid profile in Sudanese type 2 diabetic patients with cardiovascular disease: a case control study,” F1000Res., vol. 11, p. 472, Apr. 2024, doi: 10.12688/f1000research.110927.1.
[25] I. Ahmed, A. Javed, N. Ullah, and H. M. Kaifi, “Impact of Online Diabetes Education Counseling on Treatment Adherence and Quality of Life of Type-II Diabetics,” Pak. J. Med. Sci., vol. 41, no. 3, pp. 843–847, Mar. 2025, doi: 10.12669/pjms.41.3.10468.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Meilawati Diana Soetardjo, Fajar Amirulah, Muhammad Zakir Chohan, Ria Anggraeni, Widya Handayani
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
